**Testing Updates Newsletter – April 2022**

**Updates Effective April 4, 2022 or April 25, 2022**

|  |
| --- |
| **SUMMARY OF CHANGES** |
| **ORDER CODE** | **TEST NAME** | **CHANGE TYPE** | **DATE EFFECTIVE** |
| *[4i1\_PRO](#Anchor0)* | 4-in-1 Panel (PAP, HPV, CT, and NG) | Interpretive Data, Specimen Requirements | April 4, 2022 |
| *[CTEL\_CRO](#Anchor1b)* | C-Telopeptide, Beta-Cross-Linked, Serum | Specimen Requirements | April 4, 2022 |
| *[CTNG\_G](#Anchor3)* | Chlamydia and gonorrhea, Genital Swab | Inactive | April 25, 2022 |
| *[CTNG\_U](#Anchor4)* | Chlamydia and Gonorrhea, Urine | Inactive | April 25, 2022 |
| *[UR\_COCQ](#Anchor4a)* | Cocaine Metabolite, Urine, Quantitative | New Test | April 4, 2022 |
| *[COPEP](#Anchor4aa)* | Copeptin | New Test | April 4, 2022 |
| *[UDRUG7](#Anchor4b)* | Drugs of Abuse Screen Panel 7, with Reflex to Confirmation/Quantitation, Urine | Specimen Requirements | April 4, 2022 |
| *[UDRUGSO](#Anchor4c)* | Drugs of Abuse Screen Panel 9, Screen Only, Urine | Specimen Requirements | April 4, 2022 |
| *[UDRUGSR](#Anchor5)* | Drugs of Abuse Screen Panel 9, with Reflex to Confirmation/Quantitation, Urine | Specimen Requirements | April 4, 2022 |
| *[UDRUG13](#Anchor7)* | Drugs of Abuse Screen Panel 13, with Reflex to Confirmation/Quantitation, Urine | Specimen Requirements | April 4, 2022 |
| *[HEP\_BCHR](#Anchor8)* | Hepatitis B Virus Panel, Chronic with Reflex to HBsAg Confirmation | Estimated Turn-Around, Methodology, Specimen Requirements | April 4, 2022 |
| *[HBEAB](#Anchor9)* | Hepatitis Be Virus Antibody, Serum or Plasma | Estimated Turn-Around, Interpretive Data, Methodology, Specimen Requirements | April 4, 2022 |
| *[HBEAGAB](#Anchor10)* | Hepatitis Be Virus Antigen and Antibody Panel | Estimated Turn-Around, Methodology, Specimen Requirements | April 4, 2022 |
| *[MPO\_Q](#Anchor11)* | Myeloperoxidase (MPO) | New Test | April 4, 2022 |
| *[UR\_PROPQ](#Anchor12)* | Propoxyphene and Metabolite, Urine | New Test | April 4, 2022 |
| *[UR\_TRIQ](#Anchor13)* | Tricyclic Antidepressants, Quantitative, Urine | New Test | April 4, 2022 |

|  |
| --- |
| **TEST DETAILS** |

*[4i1\_PRO](#TA0)* **4-in-1 Panel (PAP, HPV, CT, and NG)**

 **Specimen Requirements:**

**Preferred Container:** SurePath Vial or ThinPrep Vial and Cobas PCR Urine Kit

**Patient Preparation:** Do not use products containing corbomer(s), including lubricants, creams and gels, prior to collection of urogenital specimens used for CTNG. It is recommended that providers collect urine prior to using the lubricant for the pelvic exam, rather than using the swab for all tests.

**Specimen Preparation:**  Collect specimen according to package instructions. Do not use products containing corbomer(s), including lubricants, creams and gels, prior to collection of urogenital specimens designated for CTNG testing. It is recommended that providers collect urine prior to using the lubricant for the pelvic exam, rather than using the swab for both tests.

**Stability**: **Cobas PCR Swab or Urine Sample**: Ambient: 12 months; Refrigerated: 12 months; Frozen: Unacceptable; **SurePath or ThinPrep**: Ambient: 30 days; Refrigerated: 30 days; Frozen: Unacceptable

**Interpretive Data:** Products containing carbomer(s), including lubricants, creams and gels may interfere with the test and should not be used during or prior to collecting urogenital specimens. Products containing carbomer(s) have been shown to generate false negative and invalid results.

*[CTEL\_CRO](#TA1b)* **C-Telopeptide, Beta-Cross-Linked, Serum**

**Specimen Requirements:**

**Patient Preparation:** Fasting specimen preferred.

**Preferred Container:** Serum Separator Tube (SST)

**Critical Instructions:** CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.

**Specimen Preparation:** Allow serum specimen to sit for 15-20 minutes at room temperature for proper clot formation. Centrifuge and separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer serum or plasma to an ARUP Standard Transport Tube.

**Volume Requirements:** 1 mL (Min: 0.5 mL)

**Unacceptable:** Hemolyzed specimens

**Stability:** A: 4 hours; R: 8 hours; F: 3 months

*[CTNG\_G](#TA3)* **Chlamydia and gonorrhea, Genital Swab**

INACTIVE – Refer to *Chlamydia and Gonorrhea Panel* (CTNG).

*[CTNG\_U](#TA4)* **Chlamydia and Gonorrhea, Urine**

INACTIVE – Refer to *Chlamydia and Gonorrhea Panel* (CTNG).

*[UR\_COCQ](#TA4a)* **Cocaine Metabolite, Urine, Quantitative**

NEW TEST

**Result Codes**:

3394-4 Benzoylecgonine, Urn, Quant

**Performing Laboratory**: ARUP Laboratories

**Ordering Recommendation:** Preferred test to follow-up presumptive results. For general screening, Cocaine, Urine with Reflex to Quantitation (UR\_COC) is preferred.

**Methodology:** Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

**Specimen Requirements:**

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:**  Submit a random urine sample in a Sterile Urine Container.

**Volume Requirements:** 3.5 mL (Min: 1.5 mL)

**Unacceptable:** Specimens exposed to repeated freeze/thaw cycles.

**Stability**: Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years

**CPT Code(s):** 80353 (Alt code: G0480)

*[COPEP](#TA4aa)* **Copeptin**

NEW TEST

**Result Codes**:

78987-5 Copeptin

**Performing Laboratory**: Quest Diagnostics

**Ordering Recommendation:** Copeptin - The Copeptin test is used in the diagnosis of central diabetes insipidus and in the differential diagnosis of central or nephrogenic diabetes insipidus. It is a reliable surrogate marker for arginine vasopressin (AVP).

**Methodology:** Immunofluorescence Assay (IFA)

**Specimen Requirements:**

**Preferred Container:** Serum Separator Tube (SST)

**Specimen Preparation:**  Allow specimen to clot completely at room temperature. Separate serum from cells as soon as possible.

**Volume Requirements:** 1.0 mL (Min: 0.5 mL)

**Unacceptable:** Gross hemolysis

**Stability**: Ambient: 24 hours; Refrigerated: 72 hours; Frozen: 28 days

**CPT Code(s):** 86255

*[UDRUG7](#TA4b)* **Drugs of Abuse Screen Panel 7, with Reflex to Confirmation/Quantitation, Urine**

**Specimen Requirements:**

**Patient Preparation:** Collect sample 2-7 hours after suspected drug use.

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:** Collect a clean catch urine sample.

**Volume Requirements:** 40 mL (Min: 30 mL)

**Unacceptable:** Leaking Specimens

**Stability**: A: Unacceptable; R: 48 hours; F: Indefinitely

*[UDRUGSO](#TA4c)* **Drugs of Abuse Screen Panel 9, Screen Only, Urine**

**Specimen Requirements:**

**Patient Preparation:** Collect sample 2-7 hours after suspected drug use.

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:** Collect a clean catch urine sample.

**Volume Requirements:** 40 mL (Min: 30 mL)

**Unacceptable:** Leaking Specimens

**Stability**: A: Unacceptable; R: 48 hours; F: Indefinitely

*[UDRUGSR](#TA5)* **Drugs of Abuse Screen Panel 9, with Reflex to Confirmation/Quantitation, Urine**

**Specimen Requirements:**

**Patient Preparation:** Collect sample 2-7 hours after suspected drug use.

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:** Collect a clean catch urine sample.

**Volume Requirements:** 40 mL (Min: 30 mL)

**Unacceptable:** Leaking Specimens

**Stability**: A: Unacceptable; R: 48 hours; F: Indefinitely

*[UDRUG13](#TA7)* **Drugs of Abuse Screen Panel 13, with Reflex to Confirmation/Quantitation, Urine**

**Specimen Requirements:**

**Patient Preparation:** Collect sample 2-7 hours after suspected drug use.

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:** Collect a clean catch urine sample.

**Volume Requirements:** 40 mL (Min: 30 mL)

**Unacceptable:** Leaking Specimens

**Stability**: A: Unacceptable; R: 48 hours; F: Indefinitely

*[HEP\_BCHR](#TA8)* **Hepatitis B Virus Panel, Chronic with Reflex to HBsAg Confirmation**

**Methodology:** Qualitative Chemiluminescent Immunoassay

**Estimated Turn-Around:** 1-2 days

**Specimen Requirements:**

**Patient Preparation:** Refer to individual components.

**Preferred Container:** Serum separator tube (SST)

**Specimen Preparation:** Allow serum specimens to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection.

**Volume Requirements:** 3.5 mL (Min: 2.5 mL)

**Unacceptable:** Heparinized plasma, specimens that are heat-inactivated, grossly hemolyzed, grossly icteric, grossly lipemic or specimens containing particulate material.

**Stability**: A: Unacceptable; R: 1 week; F: 30 days (avoid repeated freeze/thaw cycles)

*[HBEAB](#TA9)* **Hepatitis Be Virus Antibody, Serum or Plasma**

**Methodology:** Qualitative Chemiluminescent Immunoassay

**Estimated Turn-Around:** 1-2 days

**Specimen Requirements:**

**Preferred Container:** Serum separator tube (SST)

**Specimen Preparation:** Allow serum specimens to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection.

**Volume Requirements:** 1.0 mL (Min: 0.5 mL)

**Unacceptable:** Specimens that are heat-inactivated, grossly hemolyzed, grossly icteric, grossly lipemic or specimens containing particulate material.

**Stability**: A: Unacceptable; R: 1 week; F: 30 days (avoid repeated freeze/thaw cycles)

**Interpretive Data**: This assay should not be used for blood donor screening, associated reentry protocols, or for screening human cell, tissues, and cellular and tissue-based products (HCT/P).

*[HBEAGAB](#TA10)* **Hepatitis Be Virus Antigen and Antibody Panel**

**Methodology:** Qualitative Chemiluminescent Immunoassay

**Estimated Turn-Around:** 1-2 days

**Specimen Requirements:**

**Preferred Container:** Serum separator tube (SST)

**Specimen Preparation:** Allow serum specimens to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection.

**Volume Requirements:** 1.5 mL (Min: 1.0 mL)

**Unacceptable:** Specimens that are heat-inactivated, grossly hemolyzed, grossly icteric, grossly lipemic or specimens containing particulate material.

**Stability**: A: Unacceptable; R: 1 week; F: 30 days (avoid repeated freeze/thaw cycles)

*[MPO\_Q](#TA11)* **Myeloperoxidase (MPO)**

NEW TEST

 **Result Codes**:

48146-5 Myeloperoxidase (MPO)

**Performing Laboratory**: Cleveland HeartLab

**Ordering Recommendation:** Myeloperoxidase testing may be used for individuals with multiple risk factors for cardiovascular disease, or those with established disease.

**Methodology:** Turbidimetric Immunoassay (TIA)

**Specimen Requirements:**

**Preferred Container:** Lavender Top (EDTA)

**Specimen Preparation:**  Separate plasma from cells immediately or within 1 hour of collection.

**Volume Requirements:** 1.0 mL (Min: 0.5 mL)

**Unacceptable:** Specimens other than EDTA plasma; improper labeling; samples not stored properly; samples older than stability limits; gross hemolysis; gross lipemia; gross icterus

**Stability**: Ambient (15-25°C): Unacceptable; Refrigerated (2-8°C): 8 days; Frozen (-20°C): 6 months; Deep Frozen (-70°C): 6 months

**CPT Code(s):** 83876

*[UR\_PROPQ](#TA12)* **Propoxyphene and Metabolite, Urine**

NEW TEST

**Result Codes**:

3545-1 Propoxyphene Quantitation, Urine

19635-2 Norpropoxyphene Quantitation, Urine

**Performing Laboratory**: National Medical Services (NMS) via ARUP Laboratories

**Ordering Recommendation:** Use to monitor patient adherence.

**Methodology:** Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)

**Specimen Requirements:**

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:**  Submit a random urine sample in a Sterile Urine Container. Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.

**Volume Requirements:** 1.0 mL (Min: 0.7 mL)

**Unacceptable:**

**Stability**: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 3 months

**CPT Code(s):** 80367 (Alt code: G0480)

*[UR\_TRIQ](#TA13)* **Tricyclic Antidepressants, Quantitative, Urine**

NEW TEST

**Result Codes**:

16114-1 Amitriptyline, Quant, Urn

3875-2 Nortriptyline, Quant, Urn

10978-5 Amitriptyline/Nortriptyline Total, Urn

3692-1 Imipramine Quant, Urn

3534-5 Desipramine Quant, Urn

14793-4.1 Imipramine/Desipramine Total, Urn

3581-6 Doxepin Quant, Urn

12386-9 Nordoxepin Quant, Urn

19247-6 Doxepin/Nordoxepin Total, Urn

26978-7 Protriptyline Quant, Urn

3492-6 Clomipramine Quant, Urn

18470-5 Norclomipramine Quant, Urn

91606-4 Clomipramine/Norclomipramine Total, Urn

**Performing Laboratory**: ARUP Laboratories

**Ordering Recommendation:** Preferred test to follow-up presumptive results or for monitoring compliance. To optimize drug therapy, Tricyclic Antidepressants, Quantitative, Serum or Plasma (ARUP 2007549) is preferred.

**Methodology:** Quantitative Liquid Chromatography-Tandem Mass Spectrometry

**Specimen Requirements:**

**Preferred Container:** Sterile Urine Container

**Specimen Preparation:**  Submit a random urine sample in a Sterile Urine Container.

**Volume Requirements:** 2.0 mL (Min: 0.7 mL)

**Stability**: Ambient: 1 week; Refrigerated: 11 days; Frozen: 2 weeks

**CPT Code(s):** 80337 (Alt code: G0480)